Antigen-specific immunotherapy of autoimmune and allergic diseases

Current Opinion in Immunology

Volumn 22, Issue 5, 2010, Pages 609-615

  Sabatos Peyton, Catherine A ^a   Verhagen, Johan ^a   Wraith, David C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BEE VENOM; DIAPEP 277 PEPTIDE; DNA VACCINE; EPITOPE; FEL D 1 PEPTIDE; GLUTAMATE DECARBOXYLASE 65; HEAT SHOCK PROTEIN 60; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 4; JAPANESE CEDAR POLLEN; MICRORNA; MYELIN BASIC PROTEIN[82-98]; PEANUT ANTIGEN; PEPTIDE DERIVATIVE; PEPTIDE DNAJP1; PROINSULIN PEPTIDE; SPLICEOSOMAL PEPTIDE P140; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ALLERGIC ENCEPHALOMYELITIS; ALLERGY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFIC IMMUNOTHERAPY; ASTHMA; AUTOIMMUNE DISEASE; BIRCH POLLEN; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CPG ISLAND; DIABETES MELLITUS; DNA IMMUNIZATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH2 CELL; TREATMENT RESPONSE;

ALLERGENS; ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNE TOLERANCE;

EID: 78049232715     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.08.006     Document Type: Review

References (57)

1. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006, 6:476-483.
2. Akdis C.A., Akdis M., Blesken T., Wymann D., Alkan S.S., Muller U., Blaser K. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996, 98:1676-1683.
3. Skripak J.M., Nash S.D., Rowley H., Brereton N.H., Oh S., Hamilton R.G., Matsui E.C., Burks A.W., Wood R.A. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 2008, 122:1154-1160.
4. Jones S.M., Pons L., Roberts J.L., Scurlock A.M., Perry T.T., Kulis M., Shreffler W.G., Steele P., Henry K.A., Adair M., et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009, 124:292-300.
5. Mobs C., Slotosch C., Loffler H., Jakob T., Hertl M., Pfutzner W. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol 2010, 184:2194-2203.
6. Frew A.J., Powell R.J., Corrigan C.J., Durham S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:319-325.
7. Gadermaier E., Flicker S., Aberer W., Egger C., Reider N., Focke M., Vrtala S., Kundi M., Valenta R. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide. Int Arch Allergy Immunol 2010, 151:17-27.
8. Focke M., Swoboda I., Marth K., Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010, 40:385-397.
9. Muller U., Akdis C.A., Fricker M., Akdis M., Blesken T., Bettens F., Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998, 101:747-754.
10. Fellrath J.M., Kettner A., Dufour N., Frigerio C., Schneeberger D., Leimgruber A., Corradin G., Spertini F. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003, 111:854-861.
11. Campbell J.D., Buckland K.F., McMillan S.J., Kearley J., Oldfield W.L., Stern L.J., Gronlund H., van Hage M., Reynolds C.J., Boyton R.J., et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009, 206:1535-1547.
12. Ebner C., Schenk S., Najafian N., Siemann U., Steiner R., Fischer G.W., Hoffmann K., Szepfalusi Z., Scheiner O., Kraft D. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 1995, 154:1932-1940.
13. Akdis M., Verhagen J., Taylor A., Karamloo F., Karagiannidis C., Crameri R., Thunberg S., Deniz G., Valenta R., Fiebig H., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004, 199:1567-1575.
14. Meiler F., Zumkehr J., Klunker S., Ruckert B., Akdis C.A., Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008, 205:2887-2898.
15. Oldfield W.L., Larche M., Kay A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002, 360:47-53.
16. Yamanaka K., Yuta A., Kakeda M., Sasaki R., Kitagawa H., Gabazza E.C., Okubo K., Kurokawa I., Mizutani H. Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J Allergy Clin Immunol 2009, 124:842-845. e847.
17. Horiguchi S., Okamoto Y., Yonekura S., Okawa T., Yamamoto H., Kunii N., Sakurai D., Fujimura T., Nakazawa K., Yasueda H. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis. Int Arch Allergy Immunol 2008, 146:76-84.
18. Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002, 2:85-95.
19. Miller A., Lider O., Weiner H.L. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991, 174:791-798.
20. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265:1237-1240.
21. Campbell B., Vogel P.J., Fisher E., Lorenz R. Myelin basic protein administration in multiple sclerosis. Arch Neurol 1973, 29:10-15.
22. Gonsette R.E., Delmotte P., Demonty L. Failure of basic protein therapy for multiple sclerosis. J Neurol 1977, 216:27-31.
23. Romine J.S., Salk J. A study of myelin basic protein as therapeutic probe in patients with multiple sclerosis. Multiple Sclerosis 1983, 621-630. Cambridge University Press. J. Hallpike, C.W.M. Adams, W.W. Tourtellotte (Eds.).
24. Faria A.M., Weiner H.L. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999, 73:153-264.
25. Ruiz P.J., Garren H., Ruiz I.U., Hirschberg D.L., Nguyen L.V., Karpuj M.V., Cooper M.T., Mitchell D.J., Fathman C.G., Steinman L. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J Immunol 1999, 162:3336-3341.
26. Weaver D.J., Liu B., Tisch R. Plasmid DNAs encoding insulin and glutamic acid decarboxylase 65 have distinct effects on the progression of autoimmune diabetes in nonobese diabetic mice. J Immunol 2001, 167:586-592.
27. Karges W., Pechhold K., Al Dahouk S., Riegger I., Rief M., Wissmann A., Schirmbeck R., Barth C., Boehm B.O. Induction of autoimmune diabetes through insulin (but not GAD65) DNA vaccination in nonobese diabetic and in RIP-B7.1 mice. Diabetes 2002, 51:3237-3244.
28. Ho P.P., Fontoura P., Ruiz P.J., Steinman L., Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol 2003, 171:4920-4926.
29. Bar-Or A., Vollmer T., Antel J., Arnold D.L., Bodner C.A., Campagnolo D., Gianettoni J., Jalili F., Kachuck N., Lapierre Y., et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007, 64:1407-1415.
30. Garren H., Ruiz P.J., Watkins T.A., Fontoura P., Nguyen L.T., Estline E.R., Hirschberg D.L., Steinman L. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 2001, 15:15-22.
31. Tisch R., Wang B., Weaver D.J., Liu B., Bui T., Arthos J., Serreze D.V. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol 2001, 166:2122-2132.
32. Annoni A., Brown B.D., Cantore A., Sergi L.S., Naldini L., Roncarolo M.G. In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood 2009, 114:5152-5161.
33. Silver P.B., Agarwal R.K., Su S.B., Suffia I., Grajewski R.S., Luger D., Chan C.C., Mahdi R.M., Nickerson J.M., Caspi R.R. Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J Immunol 2007, 179:5146-5158.
34. Luth S., Huber S., Schramm C., Buch T., Zander S., Stadelmann C., Bruck W., Wraith D.C., Herkel J., Lohse A.W. Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J Clin Invest 2008, 118:3403-3410.
35. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., Vaarala O., Forsander G., Ivarsson S., Johansson C., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920.
36. Miller S.D., Turley D.M., Podojil J.R. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 2007, 7:665-677.
37. Smith P.A., Morris-Downes M., Heijmans N., Pryce G., Arter E., O'Neill J.K., 't Hart B., Baker D., Amor S. Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice. J Neuroimmunol 2005, 164:76-84.
38. Lutterotti A., Sospedra M., Martin R. Antigen-specific therapies in MS-current concepts and novel approaches. J Neurol Sci 2008, 274:18-22.
39. Anderton S.M., Viner N.J., Matharu P., Lowrey P.A., Wraith D.C. Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat Immunol 2002, 3:175-181.
40. Monneaux F., Hoebeke J., Sordet C., Nonn C., Briand J.P., Maillere B., Sibillia J., Muller S. Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog. J Immunol 2005, 175:5839-5847.
41. Tisch R., Wang B., Serreze D.V. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 1999, 163:1178-1187.
42. Li L., Yi Z., Wang B., Tisch R. Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination. J Immunol 2009, 183:4809-4816.
43. Sinha S., Subramanian S., Miller L., Proctor T.M., Roberts C., Burrows G.G., Vandenbark A.A., Offner H. Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand. J Neurosci 2009, 29:3816-3823.
44. Jankovic D., Kugler D.G., Sher A. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol 2010, 3:239-246.
45. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010, 10:170-181.
46. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175.
47. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000, 6:1176-1182.
48. Gabrysova L., Wraith D.C. Antigenic strength controls the generation of antigen-specific IL-10-secreting T regulatory cells. Eur J Immunol 2009, 40:1386-1395.
49. Saraiva M., Christensen J.R., Veldhoen M., Murphy T.L., Murphy K.M., O'Garra A. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 2009, 31:209-219.
50. Chang H.D., Helbig C., Tykocinski L., Kreher S., Koeck J., Niesner U., Radbruch A. Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. Eur J Immunol 2007, 37:807-817.
51. Im S.H., Hueber A., Monticelli S., Kang K.H., Rao A. Chromatin-level regulation of the IL10 gene in T cells. J Biol Chem 2004, 279:46818-46825.
52. Koffeman E.C., Genovese M., Amox D., Keogh E., Santana E., Matteson E.L., Kavanaugh A., Molitor J.A., Schiff M.H., Posever J.O., et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum 2009, 60:3207-3216.
53. Muller S., Monneaux F., Schall N., Rashkov R.K., Oparanov B.A., Wiesel P., Geiger J.M., Zimmer R. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum 2008, 58:3873-3883.
54. Thrower S.L., James L., Hall W., Green K.M., Arif S., Allen J.S., Van-Krinks C., Lozanoska-Ochser B., Marquesini L., Brown S., et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009, 155:156-165.
55. Fischer B., Elias D., Bretzel R.G., Linn T. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes-an update. Expert Opin Biol Ther 2010, 10:265-272.
56. Huurman V.A., van der Meide P.E., Duinkerken G., Willemen S., Cohen I.R., Elias D., Roep B.O. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008, 152:488-497.
57. Warren K.G., Catz I., Ferenczi L.Z., Krantz M.J. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006, 13:887-895.